Leerink Partners Initiates Coverage On Kazia Therapeutics with Outperform Rating, Announces Price Target of $30

Leerink Partners has initiated coverage on Kazia Therapeutics (NASDAQ: KZIA) with an Outperform rating. The firm has set a price target of $30 for the company's stock.